Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Open-Label Study of LB-100 in Combination With Carboplatin/Etoposide/Atezolizumab in Untreated Extensive-Stage Small Cell Lung Carcinoma

X
Trial Profile

A Phase Ib Open-Label Study of LB-100 in Combination With Carboplatin/Etoposide/Atezolizumab in Untreated Extensive-Stage Small Cell Lung Carcinoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Etoposide (Primary) ; LB 100 (Primary)
  • Indications Carcinoma; Small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Apr 2023 According to Lixte Biotechnology Holdings media release, Sarah Cannon Research Institute (SCRI) ) at Tennessee Oncology in Nashville, Tennessee, is joining this ongoing Phase 1b clinical trial initiated at City of Hope
    • 09 Mar 2022 Planned number of patients changed from 18 to 21.
    • 09 Mar 2022 Planned End Date changed from 8 Aug 2023 to 9 Mar 2026.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top